Moderna's COVID-flu combo shot outperformed existing vaccines in a late-stage trialByBruce GilUpdatedJune 10, 2024
Pfizer says its its lung cancer drug Lorbrena could be a $1 billion blockbusterByBruce GilUpdatedMay 31, 2024
Moderna's mRNA bird flu vaccine trial is close to getting U.S. government fundingByBruce GilUpdatedMay 30, 2024
Ozempic knockoffs, Pfizer's cost-cutting, and AstraZeneca’s future: Pharma news roundupByBruce GilPublishedMay 24, 2024
Pfizer plans to cut costs by $1.5 billion as demand for COVID vaccine dwindlesByBruce GilPublishedMay 22, 2024
Microsoft, Amazon, Pfizer, and others are investing a record $16 billion in FranceByBruce GilPublishedMay 13, 2024
Novavax stock skyrockets 120% on $1.2 billion vaccine deal with SanofiByRocio FabbroUpdatedMay 10, 2024
The Dow rises 200 points even though the Fed says stubborn inflation means no interest rate cuts yetByVinamrata ChaturvediUpdatedMay 1, 2024
Activist investor blasts Novavax for not using mRNA fears to boost COVID-19 vaccine salesByBruce GilUpdatedApril 15, 2024
Moderna's new cancer vax, AstraZeneca CEO's big pay, and record-high drug shortages: Pharma news round upByBruce GilPublishedApril 12, 2024
Daily Brief: Elon Musk gets deposed, Nvidia feels the AI heat from Google and IntelBySusan HowsonUpdatedApril 10, 2024
